Insmed(INSM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

INSM Insmed

交易中 06-02 12:16:14 EDT

101.55

-4.48

-4.23%

最高104.45	最低100.56	成交量78.28万
今开104.09	昨收106.03	日振幅3.67%
总市值218.88亿	流通市值195.98亿	总股本2.16亿
成交额7,970万	换手率0.41%	流通股本1.93亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"INSM","market":"US","secType":"STK","nameCN":"Insmed","latestPrice":101.545,"timestamp":1780416971387,"preClose":106.03,"halted":0,"volume":782784,"delay":0,"changeRate":-0.0422993492407809,"floatShares":193000000,"shares":215551896,"eps":-5.704373,"marketStatus":"交易中","change":-4.485,"latestTime":"06-02 12:16:14 EDT","open":104.09,"high":104.45,"low":100.56,"amount":79704381.95712,"amplitude":0.036688,"askPrice":101.69,"askSize":1,"bidPrice":101.48,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-5.704373,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1780430400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":959832000000,"exchange":"NASDAQ","adjPreClose":106.03,"preHourTrading":{"tag":"盘前","latestPrice":105.5,"preClose":106.03,"latestTime":"09:27 EDT","volume":762,"amount":79108.80546,"timestamp":1780406866037,"change":-0.53,"changeRate":-0.004999,"amplitude":0.007922},"postHourTrading":{"tag":"盘后","latestPrice":106.04,"preClose":106.03,"latestTime":"19:17 EDT","volume":38142,"amount":4044256.9919,"timestamp":1780355840871,"change":0.01,"changeRate":0.000094,"amplitude":0.000472},"volumeRatio":0.590004,"impliedVol":0.5075,"impliedVolPercentile":0.4303},"requestUrl":"/m/hq/s/INSM","defaultTab":"news","newsList":[{"id":"1104364382","title":"异动解读 | Insmed盘中大涨5.78%，RBC称抛售过度叠加富达新建仓提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1104364382","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104364382?lang=zh_cn&edition=full","pubTime":"2026-05-14 00:40","pubTimestamp":1778690455,"startTime":"0","endTime":"0","summary":"Insmed今日盘中大涨5.78%，引起了市场的广泛关注。消息面上，RBC Capital Markets发布研报指出，Insmed在第一季度财报发布后的抛售属于“过度反应”，公司核心指标表现积极。该机构维持其核心产品Brinsupri全年约13亿美元的销售预期，并保持“跑赢大盘”评级，目标价虽由220美元调整至205美元，但仍远高于当前股价。此外，富达投资披露了对Insmed的新重大持仓，机构资金的入场信号进一步提振了市场情绪。公司第一季度财报发布后，股价曾累计回撤约29%，当前分析师平均目标价仍显著高于现价，市场对前期的超跌存在修复预期，共同推动了本次股价的上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["INSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124593435","title":"异动解读 | Insmed夜盘大涨5.13%，RBC称抛售过度叠加富达新建仓提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1124593435","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124593435?lang=zh_cn&edition=full","pubTime":"2026-05-13 08:45","pubTimestamp":1778633126,"startTime":"0","endTime":"0","summary":"Insmed（股票代码：INSM）在今日夜盘交易时段出现显著上涨，涨幅达5.13%。消息面上，RBC Capital Markets发布研究报告指出，Insmed在第一季度财报发布后遭遇的抛售“过度”，公司核心业务指标表现积极，并维持其核心产品Brensupri全年约13亿美元的销售预期，同时保持“跑赢大盘”评级。此外，富达投资（FMR LLC）披露了对Insmed的新重大持仓，这一机构资金入场的信号进一步提振了市场情绪。此前，公司发布Q1财报后股价累计回撤约29%，而当前分析师平均目标价仍远高于现价，市场对前期超跌存在修复预期，共同推动了此次股价的上涨。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["INSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159726495","title":"异动解读 | Insmed盘中大涨9.80%，RBC称抛售过度叠加富达新建仓提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1159726495","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159726495?lang=zh_cn&edition=full","pubTime":"2026-05-13 01:17","pubTimestamp":1778606271,"startTime":"0","endTime":"0","summary":"Insmed(INSM)今日盘中大涨9.80%，引起了市场的广泛关注。消息面上，RBC Capital Markets发布研报指出，Insmed在Q1财报发布后的抛售\"过度\"，公司核心指标表现积极，维持其核心产品Brinsupri全年约13亿美元的销售预期，并保持\"跑赢大盘\"评级，目标价由220美元调整至205美元。此外，富达投资（FMR LLC）披露了对Insmed的新重大持仓，机构资金入场的信号进一步提振了市场情绪。此前，公司Q1财报发布后股价累计回撤约29%，而当前分析师平均目标价仍远高于现价，市场对前期超跌存在修复预期，共同推动了此次股价的显著上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["INSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170709846","title":"异动解读 | 肺病治疗药物销售额未达预期，Insmed(INSM)盘中大跌17.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=1170709846","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170709846?lang=zh_cn&edition=full","pubTime":"2026-05-07 23:34","pubTimestamp":1778168062,"startTime":"0","endTime":"0","summary":"Insmed(INSM)今日盘中股价大跌17.45%，引发了市场关注。消息面上，该公司报告其肺部疾病治疗药物Arikayce第一季度销售额为9810万美元，低于分析师平均预期的1.054亿美元，这一关键产品销售未达预期是导致股价下跌的主要原因。此外，公司表示正在持续评估美国政策变化的潜在影响，这些变化可能影响其另一款肺病治疗药物Brinsupri的国际上市时间。尽管公司季度总营收3.06亿美元高于分析师预期，但核心产品Arikayce的销售表现疲软，仍对投资者信心造成了显著冲击。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["INSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149799124","title":"Insmed股价跌幅持续扩大 现跌15.6%（此前涨幅误报为跌幅的修正说明）","url":"https://stock-news.laohu8.com/highlight/detail?id=1149799124","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149799124?lang=zh_cn&edition=full","pubTime":"2026-05-07 22:39","pubTimestamp":1778164757,"startTime":"0","endTime":"0","summary":"Insmed公司股价延续跌势并进一步下探，最新交易时段跌幅已达15.6%。此次修正系针对早前误将涨幅表述为跌幅的更正说明。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0053671581.USD","BK4139","LU0109394709.USD","INSM","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141413686","title":"财报前瞻｜Insmed本季度营收预计大幅增长，机构观点偏积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1141413686","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141413686?lang=zh_cn&edition=full","pubTime":"2026-04-30 13:38","pubTimestamp":1777527514,"startTime":"0","endTime":"0","summary":"Insmed将于2026年05月07日发布新一季财报，市场聚焦营收加速与亏损收窄节奏。公司主营业务以“产品”销售为主，预计本季度收入增长将由核心产品商业化与放量驱动。现有业务中增长动能最强的仍是“产品”板块，上季度贡献收入2.64亿美元，同比增长152.62%，体量与增速均处于高位。结合一致预期，本季度营收同比增幅超过两倍，显示渠道与支付侧对产品价值认可度在提升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Insmed本季度营收预计大幅增长，机构观点偏积极","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135444894","title":"Insmed研究未达主要及次要疗效终点 公司将终止HS项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1135444894","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135444894?lang=zh_cn&edition=full","pubTime":"2026-04-08 04:02","pubTimestamp":1775592132,"startTime":"0","endTime":"0","summary":"Insmed公司宣布，其最新研究未能达到预设的主要疗效终点和次要疗效终点指标。基于这一结果，公司决定终止HS项目的后续开发。\n该临床试验结果的公布，意味着Insmed在相关治疗领域的探索暂告一段落。公司表示将继续评估其他研发管线的进展，优化资源分配。\n此次研究数据的披露，为投资者和行业观察者提供了该公司研发进展的重要参考依据。市场将密切关注Insmed后续的战略调整和管线布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0889565916.HKD","LU0053671581.USD","BK4139","LU0320765992.SGD","INSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155274333","title":"Insmed公司：Arikayce安全性特征与已知数据一致，未发现新的安全信号","url":"https://stock-news.laohu8.com/highlight/detail?id=1155274333","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155274333?lang=zh_cn&edition=full","pubTime":"2026-03-23 19:02","pubTimestamp":1774263733,"startTime":"0","endTime":"0","summary":"Insmed公司公布的最新临床数据显示，其核心产品Arikayce的安全性特征与既往研究结果高度吻合。在持续监测过程中，未出现超出预期的药物不良反应，也未观察到任何新的安全性风险信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","INSM","LU0320765992.SGD","BK4139","LU0889565916.HKD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193003476","title":"Brensocatib获英国MHRA批准，成为首个专治非囊性纤维化支气管扩张症的药物，适用于12岁及以上患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1193003476","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193003476?lang=zh_cn&edition=full","pubTime":"2026-02-23 17:24","pubTimestamp":1771838688,"startTime":"0","endTime":"0","summary":"英国药品和保健品监管局（MHRA）已正式批准Brensocatib作为全球首款专门用于治疗12岁及以上非囊性纤维化支气管扩张症的药物。这一里程碑式的批准为长期缺乏针对性疗法的患者群体带来了新的希望。Brensocatib通过抑制中性粒细胞丝氨酸蛋白酶来减缓疾病进展，其独特的作用机制标志着支气管扩张症治疗领域的重大突破。该药物由生物制药公司Insmed研发，将显著改善患者的生活质量并降低急性加重风险。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INSM","LU0053671581.USD","BK4139","LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188243271","title":"财报前瞻｜Insmed本季度营收预计增118.23%，机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1188243271","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188243271?lang=zh_cn&edition=full","pubTime":"2026-02-12 10:13","pubTimestamp":1770862398,"startTime":"0","endTime":"0","summary":"Insmed将于2026年02月19日发布最新季度财报，市场关注产品销售增长与费用控制的权衡以及研发进展对利润的影响。市场一致预期显示，本季度Insmed总营收预计为2.24亿美元，同比增长118.23%；毛利率暂无权威一致预测；净利润或净利率无一致预测；调整后每股收益预计为-1.10美元，同比增长5.93%。从近期机构观点来看，偏乐观的声音占据主导。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Insmed本季度营收预计增118.23%，机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179116674","title":"Insmed 2025年初步营收6.06亿美元，同比增长67%","url":"https://stock-news.laohu8.com/highlight/detail?id=1179116674","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179116674?lang=zh_cn&edition=full","pubTime":"2026-01-09 21:06","pubTimestamp":1767964011,"startTime":"0","endTime":"0","summary":"1月9日，生物制药公司Insmed盘前涨超11%，此前该公司宣布了2025年强劲的初步收入结果，其中BRINSUPRI成功上市和ARIKAYCE销售超出预期成为亮点。Insmed 2025年初步未经审计的总收入达到6.064亿美元，较2024年增长67%，超过了5.22亿美元的市场共识预期。公司预计2026年ARIKAYCE全球收入将在4.5亿至4.7亿美元之间。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"87f58df0cea45f9dc7f6df99dc1f4be0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Insmed 2025年初步营收6.06亿美元，同比增长67%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INSM"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1159401717","title":"Insmed股票在盘前交易中下跌20.1%，因公司中期研究失败后停止鼻窦药物开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1159401717","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159401717?lang=zh_cn&edition=full","pubTime":"2025-12-18 18:30","pubTimestamp":1766053814,"startTime":"0","endTime":"0","summary":"Insmed股票在盘前交易中下跌20.1%，因公司中期研究失败后停止鼻窦药物开发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f9f3169eeaffd188a4d97d9b846e92ea","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0109394709.USD","LU0889565916.HKD","LU0053671581.USD","INSM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188873548","title":"美股夜盘 | 美光科技绩后涨超8%，大麻股CGC涨超13%；INSM暴跌18%，CART跌近6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1188873548","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188873548?lang=zh_cn&edition=full","pubTime":"2025-12-18 09:05","pubTimestamp":1766019931,"startTime":"0","endTime":"0","summary":"12月18日，美股夜盘时段，$美光科技(MU)$涨超8%，芯片需求旺盛，业绩与指引双双“爆表”；受此消息影响，存储概念股集体走高，$SanDisk Corp(SNDK)$涨超5%，$西部数据(WDC)$涨超2%。大麻股夜盘上涨，$Canopy Growth(CGC)$涨超13%，Tilray涨超5%。报道称特朗普拟于周四签署行政令重新归类大麻；医疗用品供应商Medline夜盘跌超2%，其上市首日股价涨超40%；","market":"us","thumbnail":"https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4543","BK4588","BK4532","BK4575","INSM","BK4554","BK4512","BK4527","BK4553","BK4566","BK4585","BK4605","BK4533","BK4579","TLRY","CART","MU","MDLN","BK4141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173952258","title":"Insmed收购二期临床准备的单克隆抗体 以应对潜在的呼吸系统及免疫与炎症相关指示","url":"https://stock-news.laohu8.com/highlight/detail?id=1173952258","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173952258?lang=zh_cn&edition=full","pubTime":"2025-12-18 05:03","pubTimestamp":1766005391,"startTime":"0","endTime":"0","summary":"Insmed收购二期临床准备的单克隆抗体 以应对潜在的呼吸系统及免疫与炎症相关指示","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","LU0109394709.USD","INSM","LU0320765992.SGD","BK4139","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168222595","title":"Insmed Inc - Brensocatib在CRSSNP的2B期Birch研究未达到主要或次要疗效指标","url":"https://stock-news.laohu8.com/highlight/detail?id=1168222595","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168222595?lang=zh_cn&edition=full","pubTime":"2025-12-18 05:03","pubTimestamp":1766005391,"startTime":"0","endTime":"0","summary":"Insmed Inc - Brensocatib在CRSSNP的2B期Birch研究未达到主要或次要疗效指标","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INSM","LU0109394709.USD","LU0889565916.HKD","LU0320765992.SGD","BK4139","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131212462","title":"纳斯达克公司：阿尔尼拉姆制药、Ferrovial、Insmed、单片电源系统、希捷科技、西部数据将被纳入纳斯达克100指数","url":"https://stock-news.laohu8.com/highlight/detail?id=1131212462","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131212462?lang=zh_cn&edition=full","pubTime":"2025-12-13 09:09","pubTimestamp":1765588155,"startTime":"0","endTime":"0","summary":"纳斯达克公司：阿尔尼拉姆制药、Ferrovial、Insmed、单片电源系统、希捷科技、西部数据将被纳入纳斯达克100指数","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"0edbc198404a72334f079a67157af149","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2087625088.SGD","LU0314104364.USD","LU0274383776.USD","LU0081259029.USD","IE00B19Z9Z06.USD","IE00B894F039.SGD","IE00B64PRP62.GBP","LU0203347892.USD","SG9999014039.USD","LU1861215975.USD","LU1992135472.HKD","BK4112","LU0444971666.USD","LU0056508442.USD","LU0353189680.USD","INSM","LU0882574055.USD","LU2210149790.SGD","LU0889565916.HKD","LU1852331112.SGD","BK4512","LU1235294995.USD","BK4139","LU2272731865.HKD","LU2210150020.SGD","BK4170","BK4141","LU1823568750.SGD","LU0353189763.USD","BK4585","LU1861220033.SGD","SG9999014013.SGD","LU2360106780.USD","LU0476273544.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","LU0006061336.USD","LU1642822529.SGD","LU0320765059.SGD","LU2360107168.USD","LU2322448957.HKD","LU0109394709.USD","LU2272731600.USD","LU0109391861.USD","LU0320765992.SGD","LU2931357623.SGD","LU1046421795.USD","LU2272731782.SGD","LU0203345920.USD","LU0708995401.HKD","BK4588","LU1815336760.USD","LU1670627923.USD","IE00BD6J9T35.USD","LU2473716301.USD","IE00BKPKM429.USD","WDC","LU2250418816.HKD","LU1035773651.USD","LU1670628061.USD","LU2089985449.USD","LU1992135399.USD","IE00B19Z9P08.USD","LU1069347547.HKD","ALNY","LU0114720955.EUR","LU2095319765.USD","NDAQ","SG9999014005.SGD","STX","LU0672654240.SGD","LU0053671581.USD","LU0444973449.USD","SG9999014021.USD","LU1267930730.SGD","LU0957808578.USD","MPWR","LU2290526834.HKD","LU2322448791.USD","BK4548","IE00BN0W2W23.USD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514113720","title":"Insmed(INSM.US)获加拿大皇家银行首次覆盖，给予优于大市评级, 目标价100.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514113720","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514113720?lang=zh_cn&edition=full","pubTime":"2025-02-26 00:23","pubTimestamp":1740500610,"startTime":"0","endTime":"0","summary":"Insmed(INSM.US)获加拿大皇家银行首次覆盖，给予优于大市评级, 目标价100.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/26002348385754.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["INSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513875615","title":"Insmed Incorporated2024财年实现净利润-9.14亿美元，同比减少21.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513875615","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513875615?lang=zh_cn&edition=full","pubTime":"2025-02-24 00:00","pubTimestamp":1740326449,"startTime":"0","endTime":"0","summary":"2月24日，Insmed Incorporated公布财报，公告显示公司2024财年净利润为-9.14亿美元，同比减少21.87%；其中营业收入为3.64亿美元，同比增加19.34%，每股基本收益为-5.57美元。从资产负债表来看，Insmed Incorporated总负债17.40亿美元，其中短期债务16.50百万美元，资产负债比为1.17，流动比率为5.45。机构评级：截至2025年2月24日，当前有15家机构对Insmed Incorporated目标价做出预测，其中目标均价为96.93美元，其中最低目标价为89.00美元，最高目标价为108.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224000118a250ce02&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224000118a250ce02&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513691213","title":"Truist Securities：维持Insmed(INSM.US)评级，由买入调整至买入评级, 目标价由105.00美元调整至108.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513691213","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513691213?lang=zh_cn&edition=full","pubTime":"2025-02-22 01:41","pubTimestamp":1740159669,"startTime":"0","endTime":"0","summary":"Truist Securities：维持Insmed(INSM.US)评级，由买入调整至买入评级, 目标价由105.00美元调整至108.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/22014148321070.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["INSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119035536","title":"异动解读 | 盘中狂泻5.11%!Insmed财报营收增长放缓、亏损扩大引发股价大跌","url":"https://stock-news.laohu8.com/highlight/detail?id=1119035536","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119035536?lang=zh_cn&edition=full","pubTime":"2025-02-20 22:37","pubTimestamp":1740062235,"startTime":"0","endTime":"0","summary":"在今日盘中交易中,生物制药公司Insmed股价大跌5.11%,引发了市场广泛关注。据分析,这与公司2024年第四季度财报表现不佳有很大关系。\n\n具体来看,Insmed上一季度销售额虽然达到1.0444亿美元、高于预期,但同比增长仅为24.79%,增速明显放缓。更为重要的是,Insmed当季每股亏损高达1.32美元,远高于分析师预期的1.17美元亏损。\n\n营收增长放缓加之亏损扩大,令投资者对Insmed的业务前景和盈利能力产生质疑,从而引发公司股价在盘中大幅下跌。Insmed面临着业绩增长乏力、成本控制不佳等一系列问题,当务之急是尽快扭转局面、实现盈利,从而重拾投资者信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["INSM"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.insmed.com","stockEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":-0.2043},{"period":"3month","weight":-0.2787},{"period":"6month","weight":-0.4872},{"period":"1year","weight":0.5206},{"period":"ytd","weight":-0.3908}],"compareEarnings":[{"period":"1week","weight":0.0173},{"period":"1month","weight":0.0526},{"period":"3month","weight":0.115},{"period":"6month","weight":0.1092},{"period":"1year","weight":0.287},{"period":"ytd","weight":0.1124}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Insmed Incorporated于1999年11月29日在弗吉尼亚州联邦注册成立，其主要行政办公室均位于新泽西州桥水。Insmed是一家以人为本的生物制药公司，致力于提供一流的首创疗法，以改变患有严重疾病的患者的生活。其商业组合和临床管线专注于三个治疗领域：呼吸系统、免疫学和炎症，以及神经和其他罕见。","yearOnYearQuotes":[{"month":1,"riseRate":0.457143,"avgChangeRate":0.066603},{"month":2,"riseRate":0.4,"avgChangeRate":0.075433},{"month":3,"riseRate":0.388889,"avgChangeRate":-0.049701},{"month":4,"riseRate":0.388889,"avgChangeRate":0.041727},{"month":5,"riseRate":0.388889,"avgChangeRate":0.059695},{"month":6,"riseRate":0.527778,"avgChangeRate":0.026164},{"month":7,"riseRate":0.485714,"avgChangeRate":0.004271},{"month":8,"riseRate":0.4,"avgChangeRate":-0.021648},{"month":9,"riseRate":0.571429,"avgChangeRate":0.032075},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.015562},{"month":11,"riseRate":0.657143,"avgChangeRate":0.105034},{"month":12,"riseRate":0.457143,"avgChangeRate":0.040841}],"exchange":"NASDAQ","name":"Insmed","nameEN":"Insmed"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.4","shortVersion":"4.42.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Insmed(INSM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Insmed(INSM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Insmed,INSM,Insmed股票,Insmed股票老虎,Insmed股票老虎国际,Insmed行情,Insmed股票行情,Insmed股价,Insmed股市,Insmed股票价格,Insmed股票交易,Insmed股票购买,Insmed股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Insmed(INSM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Insmed(INSM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}